一年一度的全球腫瘤界盛會(huì)-美國臨床腫瘤學(xué)會(huì)(ASCO)年會(huì)將于當(dāng)?shù)貢r(shí)間6月2日-6月6日召開。ASCO年會(huì)是世界上規(guī)模大,、學(xué)術(shù)水平高、具權(quán)威的臨床腫瘤學(xué)會(huì)議,,致力于癌癥的預(yù)防,、治療和改善患者管理,以展示腫瘤的基礎(chǔ)研究和臨床新研究為特點(diǎn),,討論當(dāng)前國際先進(jìn)的治療方法,。醫(yī)脈通精選了泌尿腫瘤領(lǐng)域Oral Abstract Session部分的13項(xiàng)重磅研究及Poster Session部分入選的8項(xiàng)中國研究,小編帶您先睹為快,。
口頭報(bào)告專場(Oral Abstract Session)
前列腺/睪丸/陰莖腫瘤
摘要號:LBA5000
標(biāo)題:Prostate irradiation in men with de novo, low-volume, me[x]tastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
報(bào)告人:Alberto Bossi
摘要號:5004
標(biāo)題:TALAPRO-2: Phase 3 study of talazoparib (TALA) enzalutamide (ENZA) versus placebo (PBO) ENZA as first-line (1L) treatment for patients (pts) with me[x]tastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
報(bào)告人:Karim Fizazi
摘要號:5005
標(biāo)題:LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with me[x]tastatic castration resistant prostate cancer (mCRPC).
報(bào)告人:Shahneen Sandhu
口頭報(bào)告專場(Oral Abstract Session)
LBA4619的演示及討論
摘要號:LBA4619
標(biāo)題:Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or me[x]tastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
報(bào)告人:Yohann Loriot
口頭報(bào)告專場(Oral Abstract Session)
腎臟/膀胱腫瘤
摘要號:LBA4500
標(biāo)題:Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in me[x]tastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
報(bào)告人:Toni K. Choueiri
摘要號:LBA4501
標(biāo)題:Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
報(bào)告人:Brian I. Rini
摘要號:4502
標(biāo)題:Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
報(bào)告人:Thomas E. Hutson
摘要號:4503
標(biāo)題:Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) platinum/gemcitabine (plt/gem) vs placebo plt/gem in patients (pts) with me[x]tastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.
報(bào)告人:Enrique Grande
摘要號:4504
標(biāo)題:Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA CET) for patients (pts) with me[x]tastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.
報(bào)告人:Arlene O. Siefker-Radtke
摘要號:4505
標(biāo)題:Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or me[x]tastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.
報(bào)告人:Shilpa Gupta
摘要號:4506
標(biāo)題:Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
報(bào)告人:Robert J. Motzer
摘要號:LBA4507
標(biāo)題:Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
報(bào)告人:Christian Pfister
摘要號:LBA4508
標(biāo)題:SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
報(bào)告人:Seth P. Lerner
壁報(bào)專場(Poster Session)
前列腺/睪丸/陰莖腫瘤
摘要號:5057
海報(bào)號:151
標(biāo)題:Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with me[x]tastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.
報(bào)告人:朱耀,,復(fù)旦大學(xué)附屬腫瘤醫(yī)院
摘要號:5065
海報(bào)號:159
標(biāo)題:Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.
報(bào)告人:葉定偉,復(fù)旦大學(xué)附屬腫瘤醫(yī)院
壁報(bào)專場(Poster Session)
腎臟/膀胱腫瘤
摘要號:4521
海報(bào)號:13
標(biāo)題:Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.
報(bào)告人:戴洪海,,山東省立醫(yī)院
摘要號:4533
海報(bào)號:25
標(biāo)題:Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligome[x]tastatic renal cell carcinoma.
報(bào)告人:劉洋,,中山大學(xué)腫瘤防治中心
摘要號:4543
海報(bào)號:35
標(biāo)題:Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in me[x]tastatic renal cell carcinoma.
報(bào)告人:Honglei Cui,,中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院
摘要號:4566
海報(bào)號:58
標(biāo)題:Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or me[x]tastatic urothelial carcinoma: An open-label phase 1b/2 study.
報(bào)告人:盛錫楠,北京大學(xué)腫瘤醫(yī)院
摘要號:4585
海報(bào)號:77
標(biāo)題:Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.
報(bào)告人:林天歆,,中山大學(xué)孫逸仙紀(jì)念醫(yī)院